PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|DRUG: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Sponsor: MedSIR
Collaborators: Hoffmann-La Roche